Gilead Sciences | GILD - Ebitda





Ebitda Veränderung Datum
AbbVie USD 5.37B 1.85B 2025-12
Agios Pharmaceuticals USD -120.31M 4.82M 2025-12
ALKERMES USD 80.26M 20.05M 2026-03
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 649.7M 76.5M 2026-03
BioMarin Pharmaceutical USD 146.05M 170.22M 2026-03
Bristol-Myers Squibb USD 2.88B 1.36B 2025-12
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 12.14B 4.26B 2025-12
Gilead Sciences USD 3.02B 1.01B 2025-12
GlaxoSmithKline GBP 2.77B 1.65B 2026-03
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 367.97M 46.53M 2026-03
J&J USD 7.19B 2.32B 2025-12
Merck USD 6.3B 2.09B 2025-12
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 193.3M 25.1M 2026-03
Novartis USD 5.3B 530M 2026-03
Pfizer USD 5.99B 5.23B 2026-03
PTC Therapeutics USD -70.99M 91.62M 2025-12
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.2B 718.4M 2025-12
Sanofi EUR 3.31B 3.65B 2026-03
Sarepta Therapeutics USD -252.2M 84.16M 2025-12
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.19B 195.3M 2026-03